Drugs / KX0826
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04502901 | Jan → Aug 2020 | androgenetic alopecia | Suzhou Kintor Pharmaceutical Inc | Completed | No outcome recorded |
| Phase 1 | NCT04984707 | Jan → Apr 2019 | androgenetic alopecia | Suzhou Kintor Pharmaceutical Inc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KX0826 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04502901 ↗ |
| Action | Inhibit | “investigational AR antagonist” NCT04502901 ↗ |
| Route | Topical | “KX-826 topical solution will be applied to the scalp of healthy male subjects with androgenetic alopecia.” NCT04502901 ↗ |
| Target | AR | “investigational AR antagonist” NCT04502901 ↗ |